Effect of Ristocetin or Heparin on 125I-vWF Binding to Heparin-Agarose Beads
| Competitor . | vWF Bound to Heparin (% of total) . | |
|---|---|---|
| Ristocetin (mg/mL) . | Heparin (μg/mL) . | |
| 0 | 0 | 50.4 |
| 0 | 50 | 5.3 |
| 0 | 100 | 3.1 |
| 0.35 | 0 | 51 |
| 0.7 | 0 | 49 |
| 1.4 | 0 | 49 |
| 1.4 | 50 | 7 |
| 1.4 | 100 | 4.1 |
| Competitor . | vWF Bound to Heparin (% of total) . | |
|---|---|---|
| Ristocetin (mg/mL) . | Heparin (μg/mL) . | |
| 0 | 0 | 50.4 |
| 0 | 50 | 5.3 |
| 0 | 100 | 3.1 |
| 0.35 | 0 | 51 |
| 0.7 | 0 | 49 |
| 1.4 | 0 | 49 |
| 1.4 | 50 | 7 |
| 1.4 | 100 | 4.1 |
125I-vWF binding to heparin-agarose beads was performed in the presence of varying fluid-phase heparin or ristocetin concentrations or of 1.4 mg/mL ristocetin and varying heparin concentrations. The percentage of bound vWF is shown as bound/total radioactivity as described in Materials and Methods.